AU2017275769B2 - Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof - Google Patents

Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof Download PDF

Info

Publication number
AU2017275769B2
AU2017275769B2 AU2017275769A AU2017275769A AU2017275769B2 AU 2017275769 B2 AU2017275769 B2 AU 2017275769B2 AU 2017275769 A AU2017275769 A AU 2017275769A AU 2017275769 A AU2017275769 A AU 2017275769A AU 2017275769 B2 AU2017275769 B2 AU 2017275769B2
Authority
AU
Australia
Prior art keywords
nucleic acid
expression
cas9
disease
aare
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017275769A
Other languages
English (en)
Other versions
AU2017275769A1 (en
Inventor
Jacques Mallet
Philippe Ravassard
Ché SERGUERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Institut du Cerveau
Original Assignee
Centre National de la Recherche Scientifique
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Institut du Cerveau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Commissariat à l'Énergie Atomique et Aux Énergies Alternatives, Institut du Cerveau filed Critical Centre National de la Recherche Scientifique
Publication of AU2017275769A1 publication Critical patent/AU2017275769A1/en
Application granted granted Critical
Publication of AU2017275769B2 publication Critical patent/AU2017275769B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
AU2017275769A 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof Active AU2017275769B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPEP16172964 2016-06-03
EP16172964 2016-06-03
PCT/EP2017/063549 WO2017207797A1 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof

Publications (2)

Publication Number Publication Date
AU2017275769A1 AU2017275769A1 (en) 2018-12-20
AU2017275769B2 true AU2017275769B2 (en) 2023-04-13

Family

ID=56148119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017275769A Active AU2017275769B2 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding Cas9 nuclease and uses thereof

Country Status (11)

Country Link
US (2) US20190185832A1 (enExample)
JP (2) JP7436145B2 (enExample)
KR (1) KR102317622B1 (enExample)
CN (2) CN116064534A (enExample)
AU (1) AU2017275769B2 (enExample)
BR (1) BR112018074930A2 (enExample)
CA (1) CA3025591A1 (enExample)
IL (1) IL263291B2 (enExample)
RU (1) RU2771383C2 (enExample)
SG (1) SG11201810772XA (enExample)
WO (1) WO2017207797A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019314475B2 (en) * 2018-08-01 2026-07-30 The Regents Of The University Of Colorado A Body Corporate Programmable designer therapeutic fusogenic secreted gectosome vesicles for macromolecule delivery and genome modification
CN115820654A (zh) * 2019-08-30 2023-03-21 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
CN114058689B (zh) * 2020-07-30 2024-08-20 南京市妇幼保健院 一种基因突变检测试剂盒及其应用
WO2024008776A1 (en) * 2022-07-05 2024-01-11 Nutritheragene Controlled expression of a transgene in human t or nk cells for use in cellular immunotherapy
WO2024100176A1 (en) * 2022-11-10 2024-05-16 Nutritheragene Controlled gene therapy of ocular diseases
CN116732043B (zh) * 2023-08-10 2023-10-17 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068096A1 (fr) * 2011-11-08 2013-05-16 Institut National De La Recherche Agronomique (Inra) Cassette d'expression inductible et ses utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3363902T3 (da) * 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
CN105899658B (zh) 2013-12-12 2020-02-18 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068096A1 (fr) * 2011-11-08 2013-05-16 Institut National De La Recherche Agronomique (Inra) Cassette d'expression inductible et ses utilisations

Also Published As

Publication number Publication date
RU2018142174A (ru) 2020-07-10
SG11201810772XA (en) 2018-12-28
WO2017207797A1 (en) 2017-12-07
CA3025591A1 (en) 2017-12-07
KR20190031230A (ko) 2019-03-25
AU2017275769A1 (en) 2018-12-20
BR112018074930A2 (pt) 2019-03-12
IL263291A (en) 2018-12-31
RU2771383C2 (ru) 2022-05-04
CN109906271A (zh) 2019-06-18
US20230313161A1 (en) 2023-10-05
US20190185832A1 (en) 2019-06-20
KR102317622B1 (ko) 2021-10-26
IL263291B2 (en) 2023-07-01
JP2019517262A (ja) 2019-06-24
CN116064534A (zh) 2023-05-05
RU2018142174A3 (enExample) 2020-09-30
IL263291B1 (en) 2023-03-01
JP7436145B2 (ja) 2024-02-21
JP2022133441A (ja) 2022-09-13

Similar Documents

Publication Publication Date Title
KR102317622B1 (ko) Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도
AU2016214301B2 (en) Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
CN107746845B (zh) 特异性靶向LAG-3基因的sgRNA和特异性敲除LAG-3基因的方法
CA2304642C (en) Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna
AU2017248259A1 (en) Chimeric antigen receptor T cell compositions
AU2017301609A1 (en) BCL11A homing endonuclease variants, compositions, and methods of use
KR20210102247A (ko) Crispr 수퍼-리프레서에 의한 생체내 합성 면역조절
KR20180113990A (ko) 가족성 고콜레스테롤혈증을 치료하기 위한 유전자 요법
JP7725514B2 (ja) 結節性硬化症の遺伝子治療
AU2020455080B2 (en) Vaginal gel preparation and preparation method therefor
KR20210005184A (ko) 유전자 치료 방법
US20240018542A1 (en) Co-packaging to mitigate intermolecular recombination
KR20210005178A (ko) X-연관 고 igm 증후군에서의 치료적 게놈 편집
CN106011133A (zh) 一种小的dna分子量标准物、标准物质粒及其制备方法
CN107760680B (zh) 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
AU2026202348A1 (en) Treatment of neuromuscular diseases via gene therapy that expresses Klotho protein
CN115247180A (zh) 试剂盒及其在构建毛囊组织特异表达人源II型5α-还原酶基因的重组猪细胞中的应用
CN115704023A (zh) 靶向USH2A基因pre-mRNA的gRNA、递送系统和CRISPR-Cas系统
JP2022541788A (ja) Ｈｉｖ感染症を治療するための長寿命ｔ細胞
CN115247181A (zh) 一种用于制备脱发模型猪的核移植供体细胞的试剂盒及其制备方法
RU2810116C1 (ru) Вагинальный гель и метод его изготовления
CN112272565A (zh) 使用慢病毒基因构建体的递送的体内基因疗法
US20240368632A1 (en) Cells modified by a cas12i polypeptide
CN109628487A (zh) 一种利用转基因猪唾液腺制备人神经生长因子的方法
CN117677630A (zh) 用于治疗神经退行性疾病的颗粒体蛋白/上皮素模块及其组合

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)